Levetiracetam induced hypomania: a case report.
Ali Ercan AltınozŞengül Tosun AltınözBaşak Güzel BiltekinMurat Can KayaPublished in: Therapeutic advances in drug safety (2019)
Levetiracetam (LEV) is a newer second-generation antiepileptic drug that is found to be effective in tonic-clonic seizures, partial onset seizures, and myoclonic seizures. Among antiepileptic drugs, LEV is usually known for fewer adverse drug reactions. Psychiatric disorders after the administration of LEV have been reported in the literature. There are many case reports on LEV-induced psychosis, but there are only three case reports of mania induced by LEV use. In this report, we present a case with no history of psychiatric disorder who had a hypomania episode after receiving LEV for epilepsy treatment. The development of manic symptoms with LEV therapy is unusual. Clinicians should consider monitoring patients closely for treatment-related psychological symptoms and psychotic symptoms, including the possibility of mania.
Keyphrases
- bipolar disorder
- adverse drug
- drug induced
- end stage renal disease
- sleep quality
- high glucose
- systematic review
- diabetic rats
- case report
- emergency department
- chronic kidney disease
- palliative care
- peritoneal dialysis
- combination therapy
- oxidative stress
- stem cells
- mesenchymal stem cells
- bone marrow
- replacement therapy